Drug Profile
Cannabidiol/tetrahydrocannabinol - Indaptus Therapetuics
Alternative Names: Accordion Pill- Cannabidiol/tetrahydrocannabinol; AP-cannabinoids; AP-CBD/THC; Tetrahydrocannabinol/cannabidiol - Indaptus TherapeuticsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Intec Pharma
- Developer Indaptus Therapeutics
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Fibromyalgia; Pain
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Fibromyalgia(In volunteers) in Israel (PO, Pill)
- 28 May 2022 No recent reports of development identified for phase-I development in Pain(In volunteers) in Israel (PO, Pill)
- 03 Aug 2021 Decoy Biosystems has merged with Intec Pharma to form Indaptus Therapeutics